Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Active, not recruiting Phase 3

Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)

NCT07047716 · tracked via the Priya Life Science USA tracker
Phase
Phase 3
Started
2025-07-22
Last updated
2026-08-28

Condition(s) studied

HIV Pre-exposure Prophylaxis

Investigational drug(s) / intervention(s)

Lenacapavir Injection →Lenacapavir Tablet →

Lenacapavir Injection: Administered intramuscularly

Lenacapavir Tablet: Administered orally

Study summary

The goal of this clinical study is to learn more about the study drug lenacapavir (LEN), safety, tolerability, and pharmacokinetics (how LEN is absorbed, modified, distributed, and removed from the body of the participants) of once-yearly intramuscular for HIV pre-exposure prophylaxis (PrEP) in people with an indication for PrEP.

The primary objective of this study is to evaluate the pharmacokinetics (PK) and the safety and tolerability of intramuscular (IM) every 12 months (Q12M) LEN for PrEP among people with an indication for PrEP.

Eligibility

Sex
ALL
Min age
16 Years
Max age
—
Healthy volunteers
Accepted
Key Inclusion Criteria: * At least 16 years of age at screening. * Receptive anal or vaginal sex in the past 6 months and at least 1 of the following: 1. Condomless receptive sex (vaginal or anal) with 1 or more sex partners of unknown HIV status during the past 6 months 2. For a person who has engaged in anal sex in the past 6 months: diagnosis of syphilis, gonorrhea, or chlamydia in the past 6 months 3. For a person who has engaged in vaginal sex in the past 6 months: diagnosis of syphilis or gonorrhea in the past 6 months 4. Sex with partner known to be living with HIV with an unknown or detectable viral load in the past 6 months * Negative local rapid fourth generation HIV-1/2 antibody (Ab)/antigen (Ag) test, central fourth generation HIV-1/2 Ab/Ag, and HIV-1 RNA quantitative nucleic acid amplification testing (NAAT) at screening. Key Exclusion Criteria: * Current signs or symptoms suggesting HIV infection * Acute viral hepatitis A, B, or C or evidence of chronic hepatitis B or C infection * Severe hepatic impairment or a history of or current clinical decompensated liver cirrhosis (eg, ascites, encephalopathy, variceal bleeding) * Past or current participation in HIV vaccine or HIV broadly neutralizing antibody study unless participant provides documentation of receipt of placebo (ie, not active product) * Prior use of oral LEN in the past 90 days or subcutaneous LEN in the past 18 months Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Primary outcome measure(s)

  • Plasma LEN Ctrough at Week 52 — Week 52
    Ctrough is defined as the concentration at the end of the dosing interval.
  • Percentage of Participants Experiencing Treatment-emergent Adverse Event (TEAEs) — First dose up to 30 days post last dose (approximately 3 years)
  • Percentage of Participants Experiencing Treatment-emergent Clinical Laboratory Abnormalities — First dose up to 30 days post last dose (up approximately 3 years)
  • Percentage of Participants With Discontinuation due to Adverse Event — First dose up to 30 days post last dose (approximately 3 years)

Trial sites (31)

FacilityCityRegionStatus
UAB Sexual Health Research Clinic Birmingham Alabama
UCLA Clinic Care Los Angeles California
Ruane Clinical Research Group, Inc. Los Angeles California
UCLA Vine Street Clinic Los Angeles California
Mills Clinical Research Los Angeles California
BIOS Clinical Research Palm Springs California
UCSD AntiViral Research Center (AVRC) San Diego California
Bridge HIV, San Francisco Department of Public Health San Francisco California
Yale University; School of Medicine; AIDS Program New Haven Connecticut
Whitman-Walker Institute, Inc. Washington D.C. District of Columbia
Children's National Hospital Washington D.C. District of Columbia
Midway Immunology and Research Center Ft. Pierce Florida
The ID Prevention Research Unit Miami Florida
University of South Florida - Curran Children's Health Center Tampa Florida
The Hope Clinic of Emory University Atlanta Georgia
Ponce de Leon Center Clinical Research Site Atlanta Georgia
University of Illinois-Chicago (UIC), Center for Dissemination and Implementation Sciences (CDIS) Chicago Illinois
Howard Brown Health Center Chicago Illinois
University Medical Center New Orleans Louisiana
Johns Hopkins Hospital - Clinical Research Unit Baltimore Maryland
Fenway Health Boston Massachusetts
Be Well Medical Center Berkley Michigan
Icahn School of Medicine at Mount Sinai - Clinical and Translational Research Center New York New York
ICAP at Columbia University- Bronx Prevention Center The Bronx New York
NC TraCS Institute - CTRC, University of North Carolina at Chapel Hill Chapel Hill North Carolina
Penn Prevention Unit Philadelphia Pennsylvania
Philadelphia FIGHT Community Health Centers, Jonathan Lax Treatment Center Philadelphia Pennsylvania
St. Jude Children's Research Hospital Memphis Tennessee
Central Texas Clinical Research Austin Texas
The Crofoot Research Center Houston Texas
Vaccine Trials Unit - Fred Hutchinson Cancer Center / University of Washington Seattle Washington
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07047716 on ClinicalTrials.gov ↗ ← All trials in the USA